Rebiotix Inc., a Ferring Company, is a pioneer with is microbiota-based MRT™ drug platform, which has the potential to change the way challenging diseases are treated.
Lead MRT™ drug platform product, RBX2660 is targeted at treating recurrent Clostridium difficile (C. diff.) infection. We are leveraging our years of knowledge and experience to develop MRT drug platform applications for other conditions that result from disruption of the gut microbiota.
Pipeline: RBX2660 – Enema Formulation
Pipeline: RBX7455 – Oral Formulation
Caution: Drug products are in development and investigational at this time. No product has yet been approved by the U.S. Food and Drug Administration.